BCR‐ABL tyrosine kinase inhibitors promote pathological changes in dilator phenotype in the human microvasculature
- 12 May 2020
- journal article
- research article
- Published by Wiley in Microcirculation
- Vol. 27 (7), e12625
- https://doi.org/10.1111/micc.12625
Abstract
Objective Treatment with BCR‐ABL tyrosine kinase inhibitors (TKIs) is the standard of care for patients with chronic myeloid leukemia, however evidence indicates these compounds may have cardiovascular side‐effects. This study sought to determine if ex vivo exposure of human adipose arterioles to the BCR‐ABL TKIs imatinib and nilotinib causes endothelial dysfunction. Methods Human adipose arterioles were incubated overnight in cell culture media containing vehicle (PBS), imatinib (10 µmol/L) or nilotinib (100 µmol/L). Arterioles were cannulated onto glass pipettes and flow mediated dilation (FMD) was assessed via video microscopy. To determine the mechanism of vasodilation, FMD was re‐assessed in the presence of either the nitric oxide synthase inhibitor L‐NAME (100 µmol/L) or the H2O2 scavenger PEG‐Catalase (500 U/mL). Results Neither imatinib nor nilotinib affected the magnitude of FMD (max dilation = 78±17% vehicle, 80 ± 24% nilotinib, 73 ± 13% imatinib). FMD was decreased by L‐NAME in vehicle‐treated arterioles (max dilation = 47±29%). Conversely, L‐NAME had no effect on FMD in imatinib‐ or nilotinib‐treated vessels (max dilation = 79±14% and 80 ± 24%, respectively), rather FMD was inhibited by PEG‐Catalase (max dilation = 29±11% and 29 ± 14%, respectively). Conclusion Incubating human arterioles with imatinib or nilotinib switches the mediator of FMD from vasoprotective nitric oxide to pro‐inflammatory H2O2.Keywords
Funding Information
- National Heart, Lung, and Blood Institute (R01HL113612, R01HL133029)
This publication has 22 references indexed in Scilit:
- Therapeutic Drug Monitoring of Imatinib, Nilotinib, and Dasatinib for Patients with Chronic Myeloid LeukemiaBiological & Pharmaceutical Bulletin, 2015
- The vascular renin-angiotensin system contributes to blunted vasodilation induced by transient high pressure in human adipose microvesselsAmerican Journal of Physiology-Heart and Circulatory Physiology, 2014
- Physiological Basis and Long-Term Clinical Outcome of Discordance Between Fractional Flow Reserve and Coronary Flow Velocity Reserve in Coronary Stenoses of Intermediate SeverityCirculation: Cardiovascular Interventions, 2014
- Anthracycline Causes Impaired Vascular Endothelial Function and Aortic Stiffness in Long Term Survivors of Childhood CancerPathology and Oncology Research, 2012
- Second line BCR/ABK TKI-associated severe adverse events:preferential occurrence in patients with comorbiditiesHaematologica, 2011
- Paclitaxel chemotherapy and vascular toxicity as assessed by flow-mediated and nitrate-mediated vasodilatationVascular Pharmacology, 2010
- Coronary Microvascular Reactivity to Adenosine Predicts Adverse Outcome in Women Evaluated for Suspected Ischemia: Results From the National Heart, Lung and Blood Institute WISE (Women's Ischemia Syndrome Evaluation) StudyJournal of the American College of Cardiology, 2010
- Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitorsLeukemia, 2008
- Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cellsBlood, 2007
- Potential Use of Imatinib in Ewing's Sarcoma: Evidence for In Vitro and In Vivo ActivityJNCI Journal of the National Cancer Institute, 2002